Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnostics, PCR, NGS), Disease (Hepatitis, HIV, HAI, TB, Flu, Syphilis), End User (Labs) - Global Forecast to 2030
The infectious disease diagnostics market is projected to reach USD 42.20 billion by 2030 from USD 26.58 billion in 2025, at a CAGR of 9.7% during the forecast period. The factors driving the market growth include the increasing emphasis on decentralized diagnostics and the rising demand for CLIA-waived point-of-care (PoC) tests. These trends have significantly contributed to the widespread adoption of PoC technologies. The need for efficient healthcare delivery primarily fuels the shift towards decentralized PoC testing. By relocating diagnostic testing to point-of-care settings, healthcare providers can perform diagnostics directly at the patient's side, minimizing the time between sample collection and results.
By type of testing, the PoC testing segment is expected to grow at the highest CAGR during the forecast period.
By type of testing, the infectious disease diagnostics market is segmented into laboratory and PoC testing. The PoC testing segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of this segment is attributed to the increasing investments from key companies, with a strong emphasis on innovation through product launches & strategic acquisitions. PoC testing offers several advantages over traditional laboratory testing, particularly in clinical & hospital settings. A key benefit of PoC testing is its rapid turnaround time, enabling enhanced diagnostic decisions. Moreover, PoC testing typically requires smaller sample volumes, making it less invasive and efficient.
By technology, the DNA sequencing & next-generation sequencing segment is expected to grow at the highest CAGR during the forecast period.
The infectious disease diagnostics market is segmented into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies. The DNA sequencing & next-generation sequencing segment is projected to register the highest CAGR during the forecast period. DNA sequencing is a user-friendly platform that is easily implemented in clinical settings to deliver rapid results. Its ability to analyze genetic material has expanded its potential across applications, including personalized medicine, cancer research, and drug discovery. Moreover, advancements in sequencing technologies, broadening applications across multiple domains, and the rising demand for personalized medicine are key factors expected to support the growth of this market segment in the coming years.
By region, the Asia Pacific region is projected to grow at the highest CAGR during the forecast period.
The market is segmented by region into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience the highest growth rate during the forecast period. Emerging economies in this region are seeing consistent GDP growth and a notable rise in disposable income, which has been attributed to rising healthcare spending and the uptake of advanced diagnostics. Additional growth drivers include the rising incidence & prevalence of infectious diseases, modernization of healthcare infrastructure, and the increasing adoption of advanced diagnostic technologies, particularly in rural areas.
The break-up of the profile of primary participants in the infectious disease diagnostics market:
Research Coverage:
This research report categorizes the infectious disease diagnostics market by product & service (reagents, kits, and consumables, instruments, and software & services), by type of testing (laboratory testing, PoC testing), by disease type (hepatitis, HIV, hospital-acquired infections, mosquito-borne diseases, HPV, Chlamydia trachomatis, Neisseria gonorrhea, tuberculosis, influenza, syphilis, and other infectious diseases), by sample type (blood, serum, and plasma, urine, and other sample types), by technology (immunodiagnostics, polymerase chain reaction, clinical microbiology, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies), by clinical application (diagnostics and screening), by end user (diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users), and region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report's scope covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the infectious disease diagnostics market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent infectious disease diagnostics market developments. This report covers the competitive analysis of upcoming startups in the infectious disease diagnostics market ecosystem.
Reasons to Buy this Report:
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
By type of testing, the PoC testing segment is expected to grow at the highest CAGR during the forecast period.
By type of testing, the infectious disease diagnostics market is segmented into laboratory and PoC testing. The PoC testing segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of this segment is attributed to the increasing investments from key companies, with a strong emphasis on innovation through product launches & strategic acquisitions. PoC testing offers several advantages over traditional laboratory testing, particularly in clinical & hospital settings. A key benefit of PoC testing is its rapid turnaround time, enabling enhanced diagnostic decisions. Moreover, PoC testing typically requires smaller sample volumes, making it less invasive and efficient.
By technology, the DNA sequencing & next-generation sequencing segment is expected to grow at the highest CAGR during the forecast period.
The infectious disease diagnostics market is segmented into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies. The DNA sequencing & next-generation sequencing segment is projected to register the highest CAGR during the forecast period. DNA sequencing is a user-friendly platform that is easily implemented in clinical settings to deliver rapid results. Its ability to analyze genetic material has expanded its potential across applications, including personalized medicine, cancer research, and drug discovery. Moreover, advancements in sequencing technologies, broadening applications across multiple domains, and the rising demand for personalized medicine are key factors expected to support the growth of this market segment in the coming years.
By region, the Asia Pacific region is projected to grow at the highest CAGR during the forecast period.
The market is segmented by region into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience the highest growth rate during the forecast period. Emerging economies in this region are seeing consistent GDP growth and a notable rise in disposable income, which has been attributed to rising healthcare spending and the uptake of advanced diagnostics. Additional growth drivers include the rising incidence & prevalence of infectious diseases, modernization of healthcare infrastructure, and the increasing adoption of advanced diagnostic technologies, particularly in rural areas.
The break-up of the profile of primary participants in the infectious disease diagnostics market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, the Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa- 4%
Research Coverage:
This research report categorizes the infectious disease diagnostics market by product & service (reagents, kits, and consumables, instruments, and software & services), by type of testing (laboratory testing, PoC testing), by disease type (hepatitis, HIV, hospital-acquired infections, mosquito-borne diseases, HPV, Chlamydia trachomatis, Neisseria gonorrhea, tuberculosis, influenza, syphilis, and other infectious diseases), by sample type (blood, serum, and plasma, urine, and other sample types), by technology (immunodiagnostics, polymerase chain reaction, clinical microbiology, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies), by clinical application (diagnostics and screening), by end user (diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users), and region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report's scope covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the infectious disease diagnostics market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent infectious disease diagnostics market developments. This report covers the competitive analysis of upcoming startups in the infectious disease diagnostics market ecosystem.
Reasons to Buy this Report:
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (Rising prevalence of infectious diseases, rising focus on R&D and funding investments for infectious disease diagnostic products, adoption of innovative & advanced technologies for infectious disease diagnosis, gradual shift from centralized laboratories to decentralized POC testing centers), opportunities (high growth potential of emerging economies), restraints (unfavorable reimbursements), and challenges (stringent regulatory guidelines for ivd products, operational barriers and shortage of skilled laboratory technicians) influencing the growth of the infectious disease diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the infectious disease diagnostics market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the infectious disease diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the infectious disease diagnostics market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 KEY STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key secondary sources
2.2.1.2 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 MARKET SHARE ASSESSMENT
2.6 RESEARCH ASSUMPTIONS
2.6.1 PARAMETRIC ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY 58 4 PREMIUM INSIGHTS
4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION)
4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
4.5 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2030 (USD MILLION)
4.6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
4.7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
4.8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
4.9 INFECTIOUS DISEASE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of infectious diseases
5.2.1.2 Rising focus on R&D and funding investments for infectious disease diagnostic products
5.2.1.3 Adoption of innovative & advanced technologies for infectious disease diagnosis
5.2.1.4 Gradual shift from centralized laboratories to decentralized PoC testing centers
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursements
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of emerging economies
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory guidelines for IVD products
5.2.4.2 Operational barriers and shortage of skilled laboratory technicians
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTICS PRODUCTS, 2023?2025
5.3.2 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER,2023?2025
5.3.3 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023?2025
5.4 PATENT ANALYSIS
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
5.7.2 IMPORT DATA (HS CODE 3822)
5.7.3 EXPORT DATA (HS CODE 3822)
5.8 ECOSYSTEM ANALYSIS
5.8.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.9 PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY FRAMEWORK
5.10.1.1 North America
5.10.1.1.1 US
5.10.1.1.2 Canada
5.10.1.2 Europe
5.10.1.2.1 Germany
5.10.1.2.2 UK
5.10.1.2.3 France
5.10.1.2.4 Italy
5.10.1.3 Asia Pacific
5.10.1.3.1 China
5.10.1.3.2 Japan
5.10.1.3.3 India
5.10.1.4 Latin America
5.10.1.4.1 Brazil
5.10.1.4.2 Mexico
5.10.1.5 Middle East
5.10.1.5.1 Africa
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGIES
5.11.1.1 Immunodiagnostics
5.11.2 COMPLEMENTARY TECHNOLOGIES
5.11.2.1 Polymerase Chain Reaction (PCR)
5.11.3 ADJACENT TECHNOLOGIES
5.11.3.1 Next-generation Sequencing (NGS)
5.12 KEY CONFERENCES & EVENTS, 2025–2026
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 INVESTMENT & FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT
5.16.2 CASE STUDY 2: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTIONS
5.16.3 CASE STUDY 3: RAPID DIFFERENTIATION OF VIRAL & BACTERIAL INFECTION IN PEDIATRIC PATIENTS
5.17 IMPACT OF AI/GENERATIVE AI ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.17.1 INTRODUCTION
5.17.2 MARKET POTENTIAL OF AI
5.17.3 AI-USE CASES
5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
5.17.5 FUTURE OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.18 TRUMP TARIFF IMPACT ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 KEY IMPACT ON COUNTRY/REGION
5.18.4.1 North America
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON END-USE INDUSTRIES
5.18.5.1 Diagnostic laboratories
5.18.5.2 Hospitals & clinics
5.18.5.3 Academic research institutes
6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 REAGENTS, KITS, AND CONSUMABLES
6.2.1 RECURRENT PURCHASE TO PROPEL MARKET
6.3 INSTRUMENTS
6.3.1 RAPID TECHNOLOGICAL ADVANCEMENTS FOR ADVANCED ACCURACY TO DRIVE MARKET
6.4 SOFTWARE & SERVICES
6.4.1 INCREASING FOCUS ON VALUE-ADDED SERVICES TO SUPPORT MARKET GROWTH 118 7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING
7.1 INTRODUCTION
7.2 LABORATORY TESTING
7.2.1 HIGHER SENSITIVITY & SPECIFICITY TO FUEL UPTAKE
7.3 POC TESTING
7.3.1 RAPID TURNAROUND TIME AND INCREASING CLIA APPROVALS FOR POC TESTS TO PROPEL MARKET
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE
8.1 INTRODUCTION
8.2 BLOOD, SERUM, AND PLASMA
8.2.1 HIGHER VERSATILITY, ENHANCED CLINICAL EFFICACY, AND IMPROVED REIMBURSEMENT POLICIES TO DRIVE MARKET
8.3 URINE
8.3.1 NON-INVASIVE NATURE AND ENHANCED PATIENT CONVENIENCE TO BOOST DEMAND
8.4 OTHER SAMPLE TYPES
9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE
9.1 INTRODUCTION
9.2 HEPATITIS
9.2.1 HEPATITIS B
9.2.1.1 Highly contagious infection and requirement for regular monitoring to fuel market
9.2.2 HEPATITIS C
9.2.2.1 Rising incidence of chronic HCV and supportive government initiatives to drive market
9.2.3 OTHER HEPATITIS DISEASES
9.3 HIV
9.3.1 INCREASING PREVALENCE OF AIDS TO BOOST DEMAND
9.4 HOSPITAL-ACQUIRED INFECTIONS
9.4.1 RISING BURDEN OF MRSA INFECTIONS TO FUEL MARKET
9.5 MOSQUITO-BORNE DISEASES
9.5.1 RISING INCIDENCE OF DENGUE & MALARIA TO PROPEL MARKET
9.6 HPV
9.6.1 RAPID TECHNOLOGICAL ADVANCES TO BOOST DEMAND
9.7 CHLAMYDIA TRACHOMATIS
9.7.1 INCREASING AWARENESS INITIATIVES TO SUPPORT MARKET UPTAKE
9.8 NEISSERIA GONORRHEA
9.8.1 RISING INCIDENCE OF GONORRHEA TO FUEL MARKET
9.9 TUBERCULOSIS
9.9.1 INCREASING BURDEN OF TB IN UNDERSERVED AREAS TO DRIVE MARKET 172 9.10 INFLUENZA
9.10.1 INCREASING FOCUS ON RAPID DIAGNOSIS USING POC TESTING METHODS TO FUEL MARKET
9.11 SYPHILIS
9.11.1 IMPROVED SCREENING TECHNOLOGIES TO SUPPORT MARKET UPTAKE
9.12 OTHER INFECTIOUS DISEASES
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 IMMUNODIAGNOSTICS
10.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET
10.3 CLINICAL MICROBIOLOGY
10.3.1 RAPID TURNAROUND TIME WITH HIGHER SENSITIVITY & RELIABLE RESULTS TO BOOST DEMAND
10.4 POLYMERASE CHAIN REACTION
10.4.1 CONVENIENCE & COST-EFFECTIVENESS TO FUEL UPTAKE
10.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
10.5.1 ENHANCED SUITABILITY FOR POC TESTING WITH LOW-COST FEATURES TO FUEL UPTAKE
10.6 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
10.6.1 ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND RISING FOCUS ON MOLECULAR TARGETED DRUGS TO PROPEL MARKET
10.7 DNA MICROARRAY
10.7.1 HIGH INSTRUMENT COSTS TO LIMIT MARKET
10.8 OTHER TECHNOLOGIES
11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION
11.1 INTRODUCTION
11.2 DIAGNOSTICS
11.2.1 INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING & TIMELY TREATMENT TO DRIVE MARKET
11.3 SCREENING
11.3.1 GROWING IMPORTANCE OF EARLY DISEASE DETECTION TO FUEL MARKET
12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER
12.1 INTRODUCTION
12.2 DIAGNOSTIC LABORATORIES
12.2.1 ABILITY TO CATER TO HIGH-END SPECIALTY TESTING TO PROPEL MARKET
12.3 HOSPITALS & CLINICS
12.3.1 IMPROVED REIMBURSEMENTS AND CAPABILITY OF PURCHASING ADVANCED EQUIPMENT TO DRIVE MARKET
12.4 ACADEMIC RESEARCH INSTITUTES
12.4.1 INCREASING R&D FUNDING INVESTMENTS TO FUEL MARKET
12.5 OTHER END USERS
13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
13.2.2 US
13.2.2.1 High healthcare expenditure to drive market
13.2.3 CANADA
13.2.3.1 Supportive government initiatives for infectious disease prevention to fuel market
13.3 EUROPE
13.3.1 EUROPE: MACROECONOMIC OUTLOOK
13.3.2 GERMANY
13.3.2.1 High adoption of advanced technologies to propel market
13.3.3 UK
13.3.3.1 Increasing number of diagnostic centers to fuel uptake
13.3.4 FRANCE
13.3.4.1 Rising expenditure on life sciences R&D to drive market
13.3.5 ITALY
13.3.5.1 Rising incidence of chronic diseases to boost demand
13.3.6 SPAIN
13.3.6.1 High prevalence of HIV and consolidation of diagnostic laboratories to drive market
13.3.7 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
13.4.2 CHINA
13.4.2.1 Increasing burden of hepatitis B virus cases and growing government focus on health surveillance to drive market
13.4.3 JAPAN
13.4.3.1 Presence of established healthcare system and universal reimbursement policies to fuel uptake
13.4.4 INDIA
13.4.4.1 High prevalence of TB & HIV to propel market
13.4.5 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
13.5.2 BRAZIL
13.5.2.1 Rising focus on initiating public-private investments for healthcare improvement to fuel uptake
13.5.3 MEXICO
13.5.3.1 Improving accessibility & affordability of healthcare services to support market growth
13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST & AFRICA
13.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
13.6.2 KINGDOM OF SAUDI ARABIA (KSA)
13.6.2.1 Integration of digital health systems and improvements in healthcare infrastructure to fuel market
13.6.3 UNITED ARAB EMIRATES (UAE)
13.6.3.1 Rising requirement of high-quality healthcare services to support market growth
13.6.4 REST OF MIDDLE EAST & AFRICA
14 COMPETITIVE LANDSCAPE
14.1 INTRODUCTION
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
14.3 REVENUE SHARE ANALYSIS, 2022?2024
14.4 MARKET SHARE ANALYSIS, 2024
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
14.5.5.1 Company footprint
14.5.5.2 Region footprint
14.5.5.3 Product & Service footprint
14.5.5.4 Type of testing footprint
14.5.5.5 Sample type footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
14.6.5.1 Detailed list of key startups/SMEs
14.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
14.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
14.7 COMPANY VALUATION & FINANCIAL METRICS
14.7.1 FINANCIAL METRICS
14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON
14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT/SERVICES LAUNCHES & APPROVALS
14.9.2 DEALS
14.9.3 EXPANSIONS
15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 F. HOFFMANN-LA ROCHE LTD.
15.1.1.1 Business overview
15.1.1.2 Products/Services offered
15.1.1.3 Recent developments
15.1.1.3.1 Product/Service launches & approvals
15.1.1.3.2 Deals
15.1.1.3.3 Expansions
15.1.1.4 MnM view
15.1.1.4.1 Key strengths
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses & competitive threats
15.1.2 ABBOTT
15.1.2.1 Business overview
15.1.2.2 Products/Services offered
15.1.2.3 Recent developments
15.1.2.3.1 Product/Service launches & approvals
15.1.2.3.2 Deals
15.1.2.4 MnM view
15.1.2.4.1 Key strengths
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses & competitive threats
15.1.3 DANAHER CORPORATION
15.1.3.1 Business overview
15.1.3.2 Products/Services offered
15.1.3.3 Recent developments
15.1.3.3.1 Product/Service launches & approvals
15.1.3.3.2 Deals
15.1.3.3.3 Expansions
15.1.3.4 MnM view
15.1.3.4.1 Key strengths
15.1.3.4.2 Strategic choices
15.1.3.4.3 Weaknesses & competitive threats 367 15.1.4 BIOM?RIEUX
15.1.4.1 Business overview
15.1.4.2 Products/Services offered
15.1.4.3 Recent developments
15.1.4.3.1 Product/Service launches & approvals
15.1.4.3.2 Deals
15.1.4.4 MnM view
15.1.4.4.1 Key strengths
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses & competitive threats
15.1.5 THERMO FISHER SCIENTIFIC INC.
15.1.5.1 Business overview
15.1.5.2 Products/Services offered
15.1.5.3 Recent developments
15.1.5.3.1 Product/Service launches & approvals
15.1.5.3.2 Deals
15.1.5.4 MnM view
15.1.5.4.1 Key strengths
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses & competitive threats
15.1.6 SIEMENS HEALTHINEERS AG
15.1.6.1 Business overview
15.1.6.2 Products/Services offered
15.1.6.3 Recent developments
15.1.6.3.1 Product/Service launches & approvals
15.1.6.3.2 Deals
15.1.6.3.3 Expansions
15.1.7 HOLOGIC, INC.
15.1.7.1 Business overview
15.1.7.2 Products/Services offered
15.1.7.3 Recent developments
15.1.7.3.1 Product/Service launches & approvals
15.1.7.3.2 Deals
15.1.8 BECTON, DICKINSON AND COMPANY (BD)
15.1.8.1 Business overview
15.1.8.2 Products/Services offered
15.1.8.3 Recent developments
15.1.8.3.1 Product/Service launches & approvals
15.1.8.3.2 Deals
15.1.8.3.3 Expansions 398 15.1.9 REVVITY, INC.
15.1.9.1 Business overview
15.1.9.2 Products/Services offered
15.1.9.3 Recent developments
15.1.9.3.1 Product/Service launches & approvals
15.1.10 QIAGEN N.V.
15.1.10.1 Business overview
15.1.10.2 Products/Services offered
15.1.10.3 Recent developments
15.1.10.3.1 Product/Service launches & approvals
15.1.10.3.2 Deals
15.1.10.3.3 Expansions
15.1.11 SEEGENE INC.
15.1.11.1 Business overview
15.1.11.2 Products/Services offered
15.1.11.3 Recent developments
15.1.11.3.1 Product/Service launches & approvals
15.1.11.3.2 Deals
15.1.11.3.3 Expansions
15.2 OTHER PLAYERS
15.2.1 QUIDELORTHO CORPORATION
15.2.2 GRIFOLS, S.A.
15.2.3 DIASORIN S.P.A
15.2.4 BIO-RAD LABORATORIES, INC.
15.2.5 SYSMEX CORPORATION
15.2.6 ORASURE TECHNOLOGIES, INC.
15.2.7 CO-DIAGNOSTICS, INC.
15.2.8 SD BIOSENSOR, INC.
15.2.9 BIOSYNEX SA
15.2.10 TRINITY BIOTECH
15.2.11 BRUKER (ELITECHGROUP)
15.2.12 GENETIC SIGNATURES
15.2.13 EPITOPE DIAGNOSTICS, INC.
15.2.14 TRIVITRON HEALTHCARE
15.2.15 MERIL LIFE SCIENCES PVT. LTD.
15.2.16 INBIOS INTERNATIONAL, INC.
15.2.17 UNIOGEN OY
15.2.18 VELA DIAGNOSTICS
15.2.19 MOLBIO DIAGNOSTICS LIMITED 436 16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 KEY STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key secondary sources
2.2.1.2 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 MARKET SHARE ASSESSMENT
2.6 RESEARCH ASSUMPTIONS
2.6.1 PARAMETRIC ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY 58 4 PREMIUM INSIGHTS
4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION)
4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
4.5 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2030 (USD MILLION)
4.6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
4.7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
4.8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
4.9 INFECTIOUS DISEASE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of infectious diseases
5.2.1.2 Rising focus on R&D and funding investments for infectious disease diagnostic products
5.2.1.3 Adoption of innovative & advanced technologies for infectious disease diagnosis
5.2.1.4 Gradual shift from centralized laboratories to decentralized PoC testing centers
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursements
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of emerging economies
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory guidelines for IVD products
5.2.4.2 Operational barriers and shortage of skilled laboratory technicians
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTICS PRODUCTS, 2023?2025
5.3.2 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER,2023?2025
5.3.3 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023?2025
5.4 PATENT ANALYSIS
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
5.7.2 IMPORT DATA (HS CODE 3822)
5.7.3 EXPORT DATA (HS CODE 3822)
5.8 ECOSYSTEM ANALYSIS
5.8.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.9 PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY FRAMEWORK
5.10.1.1 North America
5.10.1.1.1 US
5.10.1.1.2 Canada
5.10.1.2 Europe
5.10.1.2.1 Germany
5.10.1.2.2 UK
5.10.1.2.3 France
5.10.1.2.4 Italy
5.10.1.3 Asia Pacific
5.10.1.3.1 China
5.10.1.3.2 Japan
5.10.1.3.3 India
5.10.1.4 Latin America
5.10.1.4.1 Brazil
5.10.1.4.2 Mexico
5.10.1.5 Middle East
5.10.1.5.1 Africa
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGIES
5.11.1.1 Immunodiagnostics
5.11.2 COMPLEMENTARY TECHNOLOGIES
5.11.2.1 Polymerase Chain Reaction (PCR)
5.11.3 ADJACENT TECHNOLOGIES
5.11.3.1 Next-generation Sequencing (NGS)
5.12 KEY CONFERENCES & EVENTS, 2025–2026
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 INVESTMENT & FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT
5.16.2 CASE STUDY 2: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTIONS
5.16.3 CASE STUDY 3: RAPID DIFFERENTIATION OF VIRAL & BACTERIAL INFECTION IN PEDIATRIC PATIENTS
5.17 IMPACT OF AI/GENERATIVE AI ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.17.1 INTRODUCTION
5.17.2 MARKET POTENTIAL OF AI
5.17.3 AI-USE CASES
5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
5.17.5 FUTURE OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.18 TRUMP TARIFF IMPACT ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 KEY IMPACT ON COUNTRY/REGION
5.18.4.1 North America
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON END-USE INDUSTRIES
5.18.5.1 Diagnostic laboratories
5.18.5.2 Hospitals & clinics
5.18.5.3 Academic research institutes
6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 REAGENTS, KITS, AND CONSUMABLES
6.2.1 RECURRENT PURCHASE TO PROPEL MARKET
6.3 INSTRUMENTS
6.3.1 RAPID TECHNOLOGICAL ADVANCEMENTS FOR ADVANCED ACCURACY TO DRIVE MARKET
6.4 SOFTWARE & SERVICES
6.4.1 INCREASING FOCUS ON VALUE-ADDED SERVICES TO SUPPORT MARKET GROWTH 118 7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING
7.1 INTRODUCTION
7.2 LABORATORY TESTING
7.2.1 HIGHER SENSITIVITY & SPECIFICITY TO FUEL UPTAKE
7.3 POC TESTING
7.3.1 RAPID TURNAROUND TIME AND INCREASING CLIA APPROVALS FOR POC TESTS TO PROPEL MARKET
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE
8.1 INTRODUCTION
8.2 BLOOD, SERUM, AND PLASMA
8.2.1 HIGHER VERSATILITY, ENHANCED CLINICAL EFFICACY, AND IMPROVED REIMBURSEMENT POLICIES TO DRIVE MARKET
8.3 URINE
8.3.1 NON-INVASIVE NATURE AND ENHANCED PATIENT CONVENIENCE TO BOOST DEMAND
8.4 OTHER SAMPLE TYPES
9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE
9.1 INTRODUCTION
9.2 HEPATITIS
9.2.1 HEPATITIS B
9.2.1.1 Highly contagious infection and requirement for regular monitoring to fuel market
9.2.2 HEPATITIS C
9.2.2.1 Rising incidence of chronic HCV and supportive government initiatives to drive market
9.2.3 OTHER HEPATITIS DISEASES
9.3 HIV
9.3.1 INCREASING PREVALENCE OF AIDS TO BOOST DEMAND
9.4 HOSPITAL-ACQUIRED INFECTIONS
9.4.1 RISING BURDEN OF MRSA INFECTIONS TO FUEL MARKET
9.5 MOSQUITO-BORNE DISEASES
9.5.1 RISING INCIDENCE OF DENGUE & MALARIA TO PROPEL MARKET
9.6 HPV
9.6.1 RAPID TECHNOLOGICAL ADVANCES TO BOOST DEMAND
9.7 CHLAMYDIA TRACHOMATIS
9.7.1 INCREASING AWARENESS INITIATIVES TO SUPPORT MARKET UPTAKE
9.8 NEISSERIA GONORRHEA
9.8.1 RISING INCIDENCE OF GONORRHEA TO FUEL MARKET
9.9 TUBERCULOSIS
9.9.1 INCREASING BURDEN OF TB IN UNDERSERVED AREAS TO DRIVE MARKET 172 9.10 INFLUENZA
9.10.1 INCREASING FOCUS ON RAPID DIAGNOSIS USING POC TESTING METHODS TO FUEL MARKET
9.11 SYPHILIS
9.11.1 IMPROVED SCREENING TECHNOLOGIES TO SUPPORT MARKET UPTAKE
9.12 OTHER INFECTIOUS DISEASES
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 IMMUNODIAGNOSTICS
10.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET
10.3 CLINICAL MICROBIOLOGY
10.3.1 RAPID TURNAROUND TIME WITH HIGHER SENSITIVITY & RELIABLE RESULTS TO BOOST DEMAND
10.4 POLYMERASE CHAIN REACTION
10.4.1 CONVENIENCE & COST-EFFECTIVENESS TO FUEL UPTAKE
10.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
10.5.1 ENHANCED SUITABILITY FOR POC TESTING WITH LOW-COST FEATURES TO FUEL UPTAKE
10.6 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
10.6.1 ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND RISING FOCUS ON MOLECULAR TARGETED DRUGS TO PROPEL MARKET
10.7 DNA MICROARRAY
10.7.1 HIGH INSTRUMENT COSTS TO LIMIT MARKET
10.8 OTHER TECHNOLOGIES
11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION
11.1 INTRODUCTION
11.2 DIAGNOSTICS
11.2.1 INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING & TIMELY TREATMENT TO DRIVE MARKET
11.3 SCREENING
11.3.1 GROWING IMPORTANCE OF EARLY DISEASE DETECTION TO FUEL MARKET
12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER
12.1 INTRODUCTION
12.2 DIAGNOSTIC LABORATORIES
12.2.1 ABILITY TO CATER TO HIGH-END SPECIALTY TESTING TO PROPEL MARKET
12.3 HOSPITALS & CLINICS
12.3.1 IMPROVED REIMBURSEMENTS AND CAPABILITY OF PURCHASING ADVANCED EQUIPMENT TO DRIVE MARKET
12.4 ACADEMIC RESEARCH INSTITUTES
12.4.1 INCREASING R&D FUNDING INVESTMENTS TO FUEL MARKET
12.5 OTHER END USERS
13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
13.2.2 US
13.2.2.1 High healthcare expenditure to drive market
13.2.3 CANADA
13.2.3.1 Supportive government initiatives for infectious disease prevention to fuel market
13.3 EUROPE
13.3.1 EUROPE: MACROECONOMIC OUTLOOK
13.3.2 GERMANY
13.3.2.1 High adoption of advanced technologies to propel market
13.3.3 UK
13.3.3.1 Increasing number of diagnostic centers to fuel uptake
13.3.4 FRANCE
13.3.4.1 Rising expenditure on life sciences R&D to drive market
13.3.5 ITALY
13.3.5.1 Rising incidence of chronic diseases to boost demand
13.3.6 SPAIN
13.3.6.1 High prevalence of HIV and consolidation of diagnostic laboratories to drive market
13.3.7 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
13.4.2 CHINA
13.4.2.1 Increasing burden of hepatitis B virus cases and growing government focus on health surveillance to drive market
13.4.3 JAPAN
13.4.3.1 Presence of established healthcare system and universal reimbursement policies to fuel uptake
13.4.4 INDIA
13.4.4.1 High prevalence of TB & HIV to propel market
13.4.5 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
13.5.2 BRAZIL
13.5.2.1 Rising focus on initiating public-private investments for healthcare improvement to fuel uptake
13.5.3 MEXICO
13.5.3.1 Improving accessibility & affordability of healthcare services to support market growth
13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST & AFRICA
13.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
13.6.2 KINGDOM OF SAUDI ARABIA (KSA)
13.6.2.1 Integration of digital health systems and improvements in healthcare infrastructure to fuel market
13.6.3 UNITED ARAB EMIRATES (UAE)
13.6.3.1 Rising requirement of high-quality healthcare services to support market growth
13.6.4 REST OF MIDDLE EAST & AFRICA
14 COMPETITIVE LANDSCAPE
14.1 INTRODUCTION
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
14.3 REVENUE SHARE ANALYSIS, 2022?2024
14.4 MARKET SHARE ANALYSIS, 2024
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
14.5.5.1 Company footprint
14.5.5.2 Region footprint
14.5.5.3 Product & Service footprint
14.5.5.4 Type of testing footprint
14.5.5.5 Sample type footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
14.6.5.1 Detailed list of key startups/SMEs
14.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
14.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
14.7 COMPANY VALUATION & FINANCIAL METRICS
14.7.1 FINANCIAL METRICS
14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON
14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT/SERVICES LAUNCHES & APPROVALS
14.9.2 DEALS
14.9.3 EXPANSIONS
15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 F. HOFFMANN-LA ROCHE LTD.
15.1.1.1 Business overview
15.1.1.2 Products/Services offered
15.1.1.3 Recent developments
15.1.1.3.1 Product/Service launches & approvals
15.1.1.3.2 Deals
15.1.1.3.3 Expansions
15.1.1.4 MnM view
15.1.1.4.1 Key strengths
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses & competitive threats
15.1.2 ABBOTT
15.1.2.1 Business overview
15.1.2.2 Products/Services offered
15.1.2.3 Recent developments
15.1.2.3.1 Product/Service launches & approvals
15.1.2.3.2 Deals
15.1.2.4 MnM view
15.1.2.4.1 Key strengths
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses & competitive threats
15.1.3 DANAHER CORPORATION
15.1.3.1 Business overview
15.1.3.2 Products/Services offered
15.1.3.3 Recent developments
15.1.3.3.1 Product/Service launches & approvals
15.1.3.3.2 Deals
15.1.3.3.3 Expansions
15.1.3.4 MnM view
15.1.3.4.1 Key strengths
15.1.3.4.2 Strategic choices
15.1.3.4.3 Weaknesses & competitive threats 367 15.1.4 BIOM?RIEUX
15.1.4.1 Business overview
15.1.4.2 Products/Services offered
15.1.4.3 Recent developments
15.1.4.3.1 Product/Service launches & approvals
15.1.4.3.2 Deals
15.1.4.4 MnM view
15.1.4.4.1 Key strengths
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses & competitive threats
15.1.5 THERMO FISHER SCIENTIFIC INC.
15.1.5.1 Business overview
15.1.5.2 Products/Services offered
15.1.5.3 Recent developments
15.1.5.3.1 Product/Service launches & approvals
15.1.5.3.2 Deals
15.1.5.4 MnM view
15.1.5.4.1 Key strengths
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses & competitive threats
15.1.6 SIEMENS HEALTHINEERS AG
15.1.6.1 Business overview
15.1.6.2 Products/Services offered
15.1.6.3 Recent developments
15.1.6.3.1 Product/Service launches & approvals
15.1.6.3.2 Deals
15.1.6.3.3 Expansions
15.1.7 HOLOGIC, INC.
15.1.7.1 Business overview
15.1.7.2 Products/Services offered
15.1.7.3 Recent developments
15.1.7.3.1 Product/Service launches & approvals
15.1.7.3.2 Deals
15.1.8 BECTON, DICKINSON AND COMPANY (BD)
15.1.8.1 Business overview
15.1.8.2 Products/Services offered
15.1.8.3 Recent developments
15.1.8.3.1 Product/Service launches & approvals
15.1.8.3.2 Deals
15.1.8.3.3 Expansions 398 15.1.9 REVVITY, INC.
15.1.9.1 Business overview
15.1.9.2 Products/Services offered
15.1.9.3 Recent developments
15.1.9.3.1 Product/Service launches & approvals
15.1.10 QIAGEN N.V.
15.1.10.1 Business overview
15.1.10.2 Products/Services offered
15.1.10.3 Recent developments
15.1.10.3.1 Product/Service launches & approvals
15.1.10.3.2 Deals
15.1.10.3.3 Expansions
15.1.11 SEEGENE INC.
15.1.11.1 Business overview
15.1.11.2 Products/Services offered
15.1.11.3 Recent developments
15.1.11.3.1 Product/Service launches & approvals
15.1.11.3.2 Deals
15.1.11.3.3 Expansions
15.2 OTHER PLAYERS
15.2.1 QUIDELORTHO CORPORATION
15.2.2 GRIFOLS, S.A.
15.2.3 DIASORIN S.P.A
15.2.4 BIO-RAD LABORATORIES, INC.
15.2.5 SYSMEX CORPORATION
15.2.6 ORASURE TECHNOLOGIES, INC.
15.2.7 CO-DIAGNOSTICS, INC.
15.2.8 SD BIOSENSOR, INC.
15.2.9 BIOSYNEX SA
15.2.10 TRINITY BIOTECH
15.2.11 BRUKER (ELITECHGROUP)
15.2.12 GENETIC SIGNATURES
15.2.13 EPITOPE DIAGNOSTICS, INC.
15.2.14 TRIVITRON HEALTHCARE
15.2.15 MERIL LIFE SCIENCES PVT. LTD.
15.2.16 INBIOS INTERNATIONAL, INC.
15.2.17 UNIOGEN OY
15.2.18 VELA DIAGNOSTICS
15.2.19 MOLBIO DIAGNOSTICS LIMITED 436 16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
TABLE 4 REGIONAL HIV DATA, 2024
TABLE 5 INDICATIVE SELLING PRICING TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2023–2025
TABLE 6 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER, 2023–2025
TABLE 7 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023–2025
TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS
TABLE 9 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 10 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 13 CLASSIFICATION OF IVD DEVICES IN EUROPE
TABLE 14 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
TABLE 17 ASIA PACIFIC: LIST OF KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
TABLE 22 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY RANK
TABLE 23 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 25 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)T
TABLE 26 KEY REAGENTS, KITS, AND CONSUMABLES CURRENTLY AVAILABLE
TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)
TABLE 28 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33 KEY INSTRUMENTS CURRENTLY AVAILABLE
TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 35 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 36 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40 KEY SOFTWARE & SERVICES CURRENTLY AVAILABLE
TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 42 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
TABLE 48 KEY LABORATORY TEST TYPES CURRENTLY AVAILABLE
TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2023–2030 (USD MILLION)
TABLE 50 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 52 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 53 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55 KEY POC TESTING TYPES CURRENTLY AVAILABLE
TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2023–2030 (USD MILLION)
TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 58 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY REGION, 2023–2030 (USD MILLION)
TABLE 64 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 67 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2023–2030 (USD MILLION)
TABLE 70 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023–2030 (USD MILLION)
TABLE 76 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 82 KEY HEPATITIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 83 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 84 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 89 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 90 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION, 2023–2030 (USD MILLION)
TABLE 91 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 96 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION, 2023–2030 (USD MILLION)
TABLE 97 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 101 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 103 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108 KEY HIV TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 109 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2023–2030 (USD MILLION)
TABLE 110 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 115 KEY HAI TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 116 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 117 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122 KEY DENGUE-TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 123 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 124 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, 2023–2030 (USD MILLION)
TABLE 126 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129 KEY HPV TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 130 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2023–2030 (USD MILLION)
TABLE 131 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 132 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 137 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 138 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 140 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 141 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2023–2030 (USD MILLION)
TABLE 144 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 146 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 148 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149 KEY TUBERCULOSIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 150 GLOBAL NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023–2030 (IN MILLIONS)
TABLE 151 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 152 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 153 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 154 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157 KEY INFLUENZA TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 158 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2023–2030 (USD MILLION)
TABLE 159 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 160 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164 KEY SYPHILIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 165 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 166 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 170 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 171 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 172 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 175 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 176 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 177 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 178 KEY IMMUNODIAGNOSTICS-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 179 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 180 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 182 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 184 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185 KEY CLINICAL MICROBIOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 186 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 187 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 189 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 191 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 192 KEY POLYMERASE CHAIN REACTION-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 193 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)
TABLE 194 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 195 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 196 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 197 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 198 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 199 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 200 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 201 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 203 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 204 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 205 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 206 KEY DNA SEQUENCING & NEXT-GENERATION SEQUENCING-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 207 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
TABLE 208 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 209 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, 2023–2030 (USD MILLION)
TABLE 210 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 211 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 212 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 213 KEY DNA MICROARRAY-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 214 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2023–2030 (USD MILLION)
TABLE 215 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 216 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 217 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 218 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 219 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 220 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 221 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 222 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 223 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 224 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 225 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 226 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
TABLE 227 KEY DIAGNOSTICS PRODUCTS CURRENTLY AVAILABLE
TABLE 228 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 229 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 230 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 231 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 232 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 233 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 234 KEY SCREENING PRODUCTS CURRENTLY AVAILABLE
TABLE 235 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY REGION, 2023–2030 (USD MILLION)
TABLE 236 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 237 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 238 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 239 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 240 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 241 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 242 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 243 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 244 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 245 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 246 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 247 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 248 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 249 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 250 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 251 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 252 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 253 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 254 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 255 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 256 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 257 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 258 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 259 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 260 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 261 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 262 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 263 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 264 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 265 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 266 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 267 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 268 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 269 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
TABLE 270 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 271 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 272 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 273 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 274 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
TABLE 275 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 276 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 277 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 278 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
TABLE 279 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 280 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 281 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 282 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 283 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
TABLE 284 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 285 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 286 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
TABLE 287 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 288 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 289 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 290 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 291 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
TABLE 292 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 293 EUROPE: MACROECONOMIC INDICATORS
TABLE 294 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 295 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 296 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
TABLE 297 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 298 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 299 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 300 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 301 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
TABLE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
TABLE 4 REGIONAL HIV DATA, 2024
TABLE 5 INDICATIVE SELLING PRICING TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2023–2025
TABLE 6 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER, 2023–2025
TABLE 7 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023–2025
TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS
TABLE 9 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 10 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 13 CLASSIFICATION OF IVD DEVICES IN EUROPE
TABLE 14 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
TABLE 17 ASIA PACIFIC: LIST OF KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
TABLE 22 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY RANK
TABLE 23 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 25 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)T
TABLE 26 KEY REAGENTS, KITS, AND CONSUMABLES CURRENTLY AVAILABLE
TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)
TABLE 28 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33 KEY INSTRUMENTS CURRENTLY AVAILABLE
TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 35 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 36 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40 KEY SOFTWARE & SERVICES CURRENTLY AVAILABLE
TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 42 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
TABLE 48 KEY LABORATORY TEST TYPES CURRENTLY AVAILABLE
TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2023–2030 (USD MILLION)
TABLE 50 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 52 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 53 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55 KEY POC TESTING TYPES CURRENTLY AVAILABLE
TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2023–2030 (USD MILLION)
TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 58 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY REGION, 2023–2030 (USD MILLION)
TABLE 64 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 67 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2023–2030 (USD MILLION)
TABLE 70 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023–2030 (USD MILLION)
TABLE 76 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 82 KEY HEPATITIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 83 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 84 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 89 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 90 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION, 2023–2030 (USD MILLION)
TABLE 91 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 96 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION, 2023–2030 (USD MILLION)
TABLE 97 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 101 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 103 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108 KEY HIV TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 109 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2023–2030 (USD MILLION)
TABLE 110 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 115 KEY HAI TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 116 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 117 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122 KEY DENGUE-TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 123 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 124 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, 2023–2030 (USD MILLION)
TABLE 126 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129 KEY HPV TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 130 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2023–2030 (USD MILLION)
TABLE 131 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 132 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 137 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 138 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 140 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 141 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2023–2030 (USD MILLION)
TABLE 144 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 146 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 148 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149 KEY TUBERCULOSIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 150 GLOBAL NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023–2030 (IN MILLIONS)
TABLE 151 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 152 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 153 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 154 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157 KEY INFLUENZA TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 158 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2023–2030 (USD MILLION)
TABLE 159 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 160 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164 KEY SYPHILIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 165 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 166 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 170 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 171 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 172 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 175 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 176 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 177 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 178 KEY IMMUNODIAGNOSTICS-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 179 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 180 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 182 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 184 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185 KEY CLINICAL MICROBIOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 186 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 187 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 189 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 191 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 192 KEY POLYMERASE CHAIN REACTION-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 193 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)
TABLE 194 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 195 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 196 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 197 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 198 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 199 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 200 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 201 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 203 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 204 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 205 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 206 KEY DNA SEQUENCING & NEXT-GENERATION SEQUENCING-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 207 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
TABLE 208 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 209 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, 2023–2030 (USD MILLION)
TABLE 210 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 211 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 212 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 213 KEY DNA MICROARRAY-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 214 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2023–2030 (USD MILLION)
TABLE 215 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 216 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 217 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 218 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 219 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 220 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 221 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 222 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 223 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 224 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 225 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 226 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
TABLE 227 KEY DIAGNOSTICS PRODUCTS CURRENTLY AVAILABLE
TABLE 228 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 229 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 230 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 231 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 232 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 233 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 234 KEY SCREENING PRODUCTS CURRENTLY AVAILABLE
TABLE 235 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY REGION, 2023–2030 (USD MILLION)
TABLE 236 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 237 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 238 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 239 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 240 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 241 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 242 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 243 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 244 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 245 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 246 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 247 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 248 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 249 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 250 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 251 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 252 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 253 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 254 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 255 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 256 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 257 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 258 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 259 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 260 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 261 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 262 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 263 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 264 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 265 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 266 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 267 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 268 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 269 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
TABLE 270 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 271 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 272 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 273 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 274 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
TABLE 275 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 276 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 277 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 278 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
TABLE 279 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 280 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 281 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 282 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 283 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
TABLE 284 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 285 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 286 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
TABLE 287 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 288 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 289 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 290 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 291 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
TABLE 292 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 293 EUROPE: MACROECONOMIC INDICATORS
TABLE 294 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 295 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 296 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
TABLE 297 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 298 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 299 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 300 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 301 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
The report "Infectious Disease Diagnostics Market by Product (Instruments, Reagents, Services, Software), Application (Hepatitis C, AIDS, Tuberculosis), Technology (PCR, INAAT, DNA Sequencing, Hybridization), End User (Hospital, Laboratories) - Global Forecast to 2019".
The IDD market is poised to reach $18,156.2 million by 2019 from $12,422.8 million in 2014, at a CAGR of 7.9% from 2014 to 2019.
It provides a detailed overview of major drivers, restraints, challenges, opportunities, current market trends and strategies impacting the global market along with estimates and forecast of revenue.
Factors such as high prevalence rate of infectious diseases, increased demand for rapid diagnostic techniques due to slow turnaround time of current techniques, and the increase in government funding are driving market growth. However, rising healthcare costs and a complex regulatory framework are restraining the growth of the global IDD market.
Major players in "Infectious Disease Diagnostics Market" are:
- Thermo Fischer Scientific, Inc. (U.S.)
- Abbott Laboratories (U.S.)
- Bio-Rad Laboratories (U.S.)
- Becton, Dickinson & Company (U.S.).
On the basis of technology, the segment is divided into traditional and molecular diagnostics. Traditional methods are categorized into immunodiagnostics, microscopy, and biochemical characterization. The molecular diagnostics segment is further divided into Polymerase Chain Reaction (PCR), INAAT (Isothermal Nucleic Acid Amplification Test), Hybridization, DNA Sequencing & NGS, microarrays, and others (electrophoresis, mass spectrometry, and flow cytometry). Microarrays and INAAT are expected to be the fastest-growing markets in the forecast period. This remarkable growth is attributed to the specificity and increased efficiency of these tests.
On the basis of end-users, the market is segmented into hospital laboratories, reference labs, physician’s office labs, academics, and others (blood banks, local public health laboratories, home health agencies, nursing homes, point-of-care, self-testing). Hospital laboratories formed the major end-users of the IDD market in 2014.
On the basis of region, the IDD market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2014, North America accounted for the largest share of the IDD market, followed by Europe. Both markets are estimated to register single-digit growth rates over the next five years. However, Asia-Pacific is expected to register the highest growth rate during the forecast period, owing to the high prevalence of infectious diseases, and huge investment opportunities due to increase in healthcare expenditure. The growth of the IDD market in Asia-Pacific will revolve around China, India, Australia, and New Zealand. Countries in the Middle East will also show growth.
